Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Transgene
  6. Company
    TNG   FR0005175080

TRANSGENE

(TNG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Transgene
Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The Company also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The Company's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The Company's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).

Number of employees : 165 people.
Sales per Business
20192020Delta
Research and Development Collaboration6.5999.1%2.99100.2% -54.66%
License0.060.9%-0.01-0.2%-
EUR in Million
Sales per region
20192020Delta
France6.65100%2.98100% -55.19%
EUR in Million
Managers
Name Title Age Since
Hedi Ben Brahim Chairman & Chief Executive Officer 39 2021
Jean-Philippe Del Chief Financial Officer 40 -
Eric Quéméneur, Dr. Chief Scientific Officer & Executive VP 56 -
Hemanshu Shah, Dr. VP-Medical Affairs & International Development 59 -
Maud Brandely, Dr. VP-Clinical Operations & Regulatory Affairs 66 2016
Jean-Pierre Bizzari, Dr. Independent Director 66 2012
Benoît Habert Independent Director 55 2012
Laurence Zitvogel, Dr. Independent Director 56 2013
Antoine Béret, Dr. Independent Director 75 2016
Marie-Yvonne Landel-Meunier Independent Director 67 2017
Members of the board
Name Title Age Since
Hedi Ben Brahim Chairman & Chief Executive Officer 39 2021
Jean-Pierre Bizzari, Dr. Independent Director 66 2012
Benoît Habert Independent Director 55 2012
Laurence Zitvogel, Dr. Independent Director 56 2013
Jean-Luc Bélingard Director 71 2013
Alain Mérieux Honorary Chairman 83 2019
Antoine Béret, Dr. Independent Director 75 2016
Marie-Yvonne Landel-Meunier Independent Director 67 2017
Maya R. Said, Dr. Independent Director 43 2017
Sandrine Flory Director - 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 97,771,334 43,056,830 44.0% 0 0.0% 44.0%
Shareholders
NameEquities%
Compagnie Merieux Alliance SAS 50,323,665 51.5%
Dassault Family 4,144,856 4.24%
BFT Investment Managers SA 350,000 0.36%
La Banque Postale Asset Management SA 244,101 0.25%
OFI Asset Management SA 240,000 0.25%
Transgene SA 164,183 0.17%
Benoît Habert 74,403 0.076%
Financière de l'Arc SAS 45,000 0.046%
Gestys SA 40,000 0.041%
Inversis Gestión SGIIC SA 16,667 0.017%
Holdings
NameEquities%Valuation
TRANSGENE (TNG) 164,183 0.17% 456,672 USD
Markets and indexes
- PEA / SRD eligible : YES / YES
- Compartiment C
- CAC Small / CAC All Shares, CAC All-Tradable, CAC Mid Small, Next Biotech, PEA
Stock Exchange Codes
- Bloomberg Code :  TNG:FP
- Reuters Code :  TRNG.PA
- Datastream Code :  F:TRN
Company contact information
Transgene
Parc d'Innovation 400 Boulevard Gonthier d Andernach
FR-67405 Illkirch Graffenstaden Cedex

Phone : +33 (0)3 88 27 91 00
Fax : +33 (0)3 88 27 91 11
web site : http://www.transgene.fr
Brand Portfolio
In partnership withAllbrands.markets
More brands of Transgene
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
TRANSGENE44.42%269
GILEAD SCIENCES, INC.16.25%84 921
BIONTECH SE258.67%70 618
WUXI APPTEC CO., LTD.23.63%64 231
REGENERON PHARMACEUTICALS22.57%61 565
VERTEX PHARMACEUTICALS-22.12%47 753
BEIGENE, LTD.48.47%35 804
GENMAB A/S19.57%30 012
ARGENX SE1.57%14 681
ACCELERON PHARMA INC.35.83%10 626
MIRATI THERAPEUTICS, INC.-14.36%9 710
NEUROCRINE BIOSCIENCES, INC.6.25%9 639
HUALAN BIOLOGICAL ENGINEERING INC.-31.96%8 214
ASCENDIS PHARMA A/S-16.21%7 948
LEGEND BIOTECH CORPORATION85.62%6 952
GW PHARMACEUTICALS PLC89.72%6 907
ARROWHEAD PHARMACEUTICALS, INC.-13.87%6 890
EXELIXIS, INC.7.92%6 824
SAREPTA THERAPEUTICS, INC.-54.26%6 781
REMEGEN CO., LTD.6.63%6 382
ALLAKOS INC.-20.08%6 042